Concepts (252)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Information Dissemination | 15 | 2024 | 194 | 4.830 |
Why?
|
| Informed Consent | 9 | 2024 | 351 | 1.730 |
Why?
|
| Bioethics | 6 | 2020 | 84 | 1.380 |
Why?
|
| Databases, Genetic | 3 | 2019 | 504 | 1.360 |
Why?
|
| Health Care Rationing | 2 | 2024 | 58 | 1.230 |
Why?
|
| Genetic Testing | 9 | 2026 | 1106 | 1.170 |
Why?
|
| Confidentiality | 5 | 2019 | 108 | 1.100 |
Why?
|
| Public Policy | 6 | 2016 | 55 | 1.050 |
Why?
|
| Medical Informatics | 5 | 2019 | 107 | 1.040 |
Why?
|
| Ethics Committees, Clinical | 3 | 2024 | 19 | 1.000 |
Why?
|
| Stakeholder Participation | 4 | 2025 | 35 | 0.960 |
Why?
|
| Health Equity | 2 | 2024 | 78 | 0.920 |
Why?
|
| Ethics Committees | 1 | 2024 | 3 | 0.870 |
Why?
|
| Charities | 1 | 2024 | 5 | 0.870 |
Why?
|
| Uncompensated Care | 1 | 2024 | 11 | 0.870 |
Why?
|
| Resource Allocation | 1 | 2024 | 53 | 0.850 |
Why?
|
| Direct-To-Consumer Screening and Testing | 2 | 2022 | 14 | 0.810 |
Why?
|
| Privacy | 2 | 2021 | 26 | 0.790 |
Why?
|
| Embryo Research | 4 | 2009 | 8 | 0.720 |
Why?
|
| Genetic Research | 2 | 2019 | 58 | 0.680 |
Why?
|
| Computer Security | 2 | 2018 | 32 | 0.670 |
Why?
|
| Genetic Privacy | 2 | 2018 | 39 | 0.670 |
Why?
|
| Ethics Consultation | 4 | 2016 | 32 | 0.670 |
Why?
|
| Communication | 4 | 2026 | 543 | 0.650 |
Why?
|
| Parents | 5 | 2026 | 1128 | 0.640 |
Why?
|
| Mentoring | 1 | 2022 | 85 | 0.640 |
Why?
|
| Genetics | 1 | 2020 | 24 | 0.630 |
Why?
|
| Patents as Topic | 2 | 2017 | 18 | 0.630 |
Why?
|
| Mentors | 1 | 2022 | 170 | 0.630 |
Why?
|
| Scholarly Communication | 1 | 2020 | 7 | 0.630 |
Why?
|
| Anemia, Sickle Cell | 1 | 2024 | 334 | 0.630 |
Why?
|
| Embryonic Stem Cells | 3 | 2009 | 157 | 0.610 |
Why?
|
| Biomedical Research | 4 | 2019 | 561 | 0.610 |
Why?
|
| Ethics, Clinical | 2 | 2022 | 86 | 0.610 |
Why?
|
| Humans | 62 | 2026 | 131163 | 0.610 |
Why?
|
| Decision Making | 5 | 2026 | 726 | 0.590 |
Why?
|
| Databases, Nucleic Acid | 1 | 2019 | 70 | 0.570 |
Why?
|
| Biomedical Technology | 1 | 2019 | 38 | 0.570 |
Why?
|
| Personally Identifiable Information | 1 | 2018 | 1 | 0.570 |
Why?
|
| Genotype | 1 | 2024 | 2595 | 0.550 |
Why?
|
| Schools | 1 | 2019 | 239 | 0.520 |
Why?
|
| Mental Health | 1 | 2021 | 378 | 0.520 |
Why?
|
| Public Health | 1 | 2019 | 269 | 0.520 |
Why?
|
| Ethicists | 4 | 2022 | 56 | 0.510 |
Why?
|
| Health Policy | 2 | 2019 | 234 | 0.510 |
Why?
|
| Homocysteine | 1 | 2017 | 116 | 0.510 |
Why?
|
| Patients | 3 | 2018 | 122 | 0.500 |
Why?
|
| Physician-Patient Relations | 3 | 2024 | 441 | 0.500 |
Why?
|
| United States | 18 | 2021 | 12072 | 0.480 |
Why?
|
| Autistic Disorder | 1 | 2020 | 398 | 0.480 |
Why?
|
| Federal Government | 1 | 2016 | 20 | 0.470 |
Why?
|
| Public Opinion | 1 | 2016 | 64 | 0.470 |
Why?
|
| Internationality | 1 | 2016 | 128 | 0.470 |
Why?
|
| Clinical Medicine | 1 | 2016 | 20 | 0.470 |
Why?
|
| Minors | 1 | 2015 | 6 | 0.470 |
Why?
|
| Parental Consent | 1 | 2015 | 24 | 0.460 |
Why?
|
| Patient Participation | 5 | 2026 | 254 | 0.450 |
Why?
|
| United States Food and Drug Administration | 1 | 2016 | 158 | 0.450 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 339 | 0.450 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 351 | 0.450 |
Why?
|
| Research Subjects | 1 | 2015 | 54 | 0.450 |
Why?
|
| Physician's Role | 2 | 2024 | 164 | 0.440 |
Why?
|
| Moral Obligations | 2 | 2013 | 83 | 0.430 |
Why?
|
| National Institutes of Health (U.S.) | 3 | 2009 | 136 | 0.430 |
Why?
|
| Advisory Committees | 4 | 2009 | 150 | 0.420 |
Why?
|
| Internship and Residency | 1 | 2024 | 1223 | 0.410 |
Why?
|
| Quality Improvement | 1 | 2020 | 722 | 0.410 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2016 | 889 | 0.410 |
Why?
|
| Vaccination | 1 | 2019 | 1060 | 0.410 |
Why?
|
| Neoplasms | 6 | 2026 | 3016 | 0.400 |
Why?
|
| Chromosome Mapping | 1 | 2016 | 1046 | 0.400 |
Why?
|
| Disclosure | 4 | 2024 | 150 | 0.390 |
Why?
|
| Pandemics | 1 | 2020 | 1118 | 0.380 |
Why?
|
| Blood Glucose | 1 | 2017 | 1117 | 0.380 |
Why?
|
| Genomics | 8 | 2026 | 1621 | 0.380 |
Why?
|
| Genetic Counseling | 3 | 2026 | 237 | 0.380 |
Why?
|
| Truth Disclosure | 1 | 2014 | 107 | 0.380 |
Why?
|
| Fear | 1 | 2014 | 190 | 0.370 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2014 | 124 | 0.370 |
Why?
|
| Policy Making | 2 | 2019 | 63 | 0.370 |
Why?
|
| Ventricular Function | 1 | 2013 | 81 | 0.360 |
Why?
|
| Treatment Refusal | 1 | 2013 | 80 | 0.360 |
Why?
|
| Continuity of Patient Care | 1 | 2014 | 143 | 0.360 |
Why?
|
| Polycystic Kidney, Autosomal Recessive | 1 | 2012 | 10 | 0.360 |
Why?
|
| Fetal Viability | 1 | 2012 | 29 | 0.350 |
Why?
|
| Neurosciences | 2 | 2024 | 53 | 0.350 |
Why?
|
| Preimplantation Diagnosis | 1 | 2012 | 29 | 0.350 |
Why?
|
| Guidelines as Topic | 2 | 2009 | 198 | 0.340 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 1129 | 0.330 |
Why?
|
| Oncologists | 2 | 2023 | 32 | 0.320 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 1692 | 0.320 |
Why?
|
| Fertilization in Vitro | 1 | 2012 | 155 | 0.320 |
Why?
|
| Algorithms | 1 | 2017 | 1680 | 0.310 |
Why?
|
| Decision Support Techniques | 1 | 2013 | 293 | 0.300 |
Why?
|
| Patient Discharge | 1 | 2014 | 514 | 0.300 |
Why?
|
| Information Technology | 2 | 2019 | 9 | 0.290 |
Why?
|
| Government Regulation | 1 | 2009 | 44 | 0.290 |
Why?
|
| Chimera | 1 | 2009 | 79 | 0.290 |
Why?
|
| Patient Selection | 1 | 2013 | 729 | 0.290 |
Why?
|
| Community Participation | 2 | 2019 | 42 | 0.280 |
Why?
|
| Pluripotent Stem Cells | 1 | 2009 | 83 | 0.280 |
Why?
|
| Social Responsibility | 3 | 2024 | 86 | 0.270 |
Why?
|
| Physicians | 2 | 2018 | 635 | 0.260 |
Why?
|
| Embryo, Mammalian | 2 | 2009 | 403 | 0.250 |
Why?
|
| Ethical Analysis | 2 | 2019 | 57 | 0.250 |
Why?
|
| Social Justice | 2 | 2024 | 65 | 0.250 |
Why?
|
| Heart-Assist Devices | 2 | 2013 | 1020 | 0.250 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2017 | 1459 | 0.250 |
Why?
|
| Policy | 2 | 2024 | 39 | 0.240 |
Why?
|
| Translating | 1 | 2026 | 30 | 0.240 |
Why?
|
| Ethics, Medical | 4 | 2016 | 400 | 0.240 |
Why?
|
| Autopsy | 2 | 2016 | 111 | 0.240 |
Why?
|
| Communication Barriers | 1 | 2026 | 47 | 0.230 |
Why?
|
| Bioethical Issues | 1 | 2005 | 23 | 0.230 |
Why?
|
| Surveys and Questionnaires | 6 | 2026 | 4066 | 0.230 |
Why?
|
| Cybernetics | 1 | 2005 | 1 | 0.220 |
Why?
|
| Embryo Disposition | 1 | 2005 | 1 | 0.220 |
Why?
|
| Legislation, Medical | 1 | 2005 | 15 | 0.220 |
Why?
|
| Adoption | 1 | 2005 | 18 | 0.220 |
Why?
|
| Expert Testimony | 1 | 2005 | 34 | 0.220 |
Why?
|
| Managed Care Programs | 1 | 2005 | 54 | 0.220 |
Why?
|
| Embryo Transfer | 1 | 2005 | 48 | 0.210 |
Why?
|
| Goals | 1 | 2005 | 126 | 0.210 |
Why?
|
| Biological Specimen Banks | 1 | 2005 | 72 | 0.210 |
Why?
|
| Ecosystem | 1 | 2024 | 91 | 0.210 |
Why?
|
| Stem Cells | 1 | 2009 | 702 | 0.210 |
Why?
|
| Frontotemporal Lobar Degeneration | 1 | 2024 | 13 | 0.210 |
Why?
|
| Insurance Benefits | 1 | 2004 | 4 | 0.210 |
Why?
|
| Professional Role | 1 | 2005 | 78 | 0.210 |
Why?
|
| Self Efficacy | 1 | 2025 | 211 | 0.210 |
Why?
|
| Patient Preference | 1 | 2026 | 151 | 0.200 |
Why?
|
| Neurophysiology | 1 | 2023 | 22 | 0.200 |
Why?
|
| HIV Infections | 1 | 2015 | 2049 | 0.190 |
Why?
|
| Terminology as Topic | 1 | 2005 | 226 | 0.190 |
Why?
|
| Insurance, Health | 1 | 2004 | 146 | 0.190 |
Why?
|
| Insurance Coverage | 1 | 2004 | 120 | 0.190 |
Why?
|
| Health Insurance Portability and Accountability Act | 2 | 2017 | 21 | 0.180 |
Why?
|
| General Surgery | 1 | 2024 | 224 | 0.170 |
Why?
|
| Sequence Analysis, RNA | 1 | 2024 | 407 | 0.170 |
Why?
|
| National Institute of Mental Health (U.S.) | 1 | 2021 | 13 | 0.170 |
Why?
|
| RNA | 1 | 2024 | 517 | 0.170 |
Why?
|
| Health Personnel | 1 | 2025 | 541 | 0.160 |
Why?
|
| Coroners and Medical Examiners | 2 | 2016 | 15 | 0.150 |
Why?
|
| Surgeons | 1 | 2024 | 289 | 0.150 |
Why?
|
| Ownership | 1 | 2019 | 33 | 0.150 |
Why?
|
| Heart Failure | 1 | 2013 | 2332 | 0.150 |
Why?
|
| Education, Medical, Graduate | 1 | 2024 | 554 | 0.150 |
Why?
|
| Fellowships and Scholarships | 1 | 2022 | 327 | 0.140 |
Why?
|
| Bangladesh | 1 | 2017 | 28 | 0.130 |
Why?
|
| Military Personnel | 1 | 2020 | 219 | 0.130 |
Why?
|
| Genes, BRCA2 | 1 | 2017 | 49 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 275 | 0.130 |
Why?
|
| Genes, BRCA1 | 1 | 2017 | 60 | 0.130 |
Why?
|
| Female | 11 | 2026 | 70963 | 0.120 |
Why?
|
| Hospital Administrators | 1 | 2016 | 9 | 0.120 |
Why?
|
| State Government | 1 | 2015 | 33 | 0.110 |
Why?
|
| Chemoprevention | 1 | 2015 | 49 | 0.110 |
Why?
|
| Adolescent | 7 | 2026 | 20987 | 0.110 |
Why?
|
| Professional Competence | 2 | 2014 | 97 | 0.110 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2015 | 95 | 0.110 |
Why?
|
| Radiation Oncology | 1 | 2014 | 30 | 0.110 |
Why?
|
| Cadaver | 2 | 2016 | 114 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2024 | 3436 | 0.110 |
Why?
|
| Politics | 2 | 2005 | 62 | 0.100 |
Why?
|
| Orbital Neoplasms | 1 | 2014 | 50 | 0.100 |
Why?
|
| Radiotherapy | 1 | 2014 | 119 | 0.100 |
Why?
|
| Licensure | 1 | 2014 | 14 | 0.100 |
Why?
|
| Exome | 1 | 2018 | 1061 | 0.100 |
Why?
|
| Forecasting | 2 | 2019 | 351 | 0.100 |
Why?
|
| Ovarian Neoplasms | 1 | 2017 | 420 | 0.100 |
Why?
|
| Certification | 1 | 2014 | 71 | 0.100 |
Why?
|
| Writing | 1 | 2014 | 59 | 0.100 |
Why?
|
| Male | 10 | 2026 | 64957 | 0.100 |
Why?
|
| Adult | 9 | 2026 | 31282 | 0.090 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2024 | 919 | 0.090 |
Why?
|
| Clinical Decision-Making | 1 | 2014 | 314 | 0.090 |
Why?
|
| Attitude of Health Personnel | 2 | 2020 | 707 | 0.090 |
Why?
|
| Brain | 1 | 2023 | 3175 | 0.090 |
Why?
|
| Rhabdomyosarcoma | 1 | 2014 | 231 | 0.090 |
Why?
|
| Shock, Cardiogenic | 1 | 2013 | 176 | 0.080 |
Why?
|
| Recovery of Function | 1 | 2013 | 449 | 0.080 |
Why?
|
| Research Embryo Creation | 1 | 2009 | 1 | 0.080 |
Why?
|
| Ethics Committees, Research | 1 | 2009 | 30 | 0.070 |
Why?
|
| Financing, Government | 1 | 2009 | 33 | 0.070 |
Why?
|
| Research Support as Topic | 1 | 2009 | 61 | 0.070 |
Why?
|
| Ethics, Research | 1 | 2009 | 59 | 0.070 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 3829 | 0.070 |
Why?
|
| Young Adult | 4 | 2026 | 10103 | 0.070 |
Why?
|
| Health Services Accessibility | 2 | 2024 | 712 | 0.070 |
Why?
|
| Stem Cell Transplantation | 1 | 2009 | 227 | 0.060 |
Why?
|
| Quality of Life | 2 | 2013 | 2082 | 0.060 |
Why?
|
| Tissue and Organ Procurement | 1 | 2009 | 254 | 0.060 |
Why?
|
| Committee Membership | 1 | 2005 | 3 | 0.060 |
Why?
|
| Dissent and Disputes | 1 | 2005 | 31 | 0.060 |
Why?
|
| Cultural Competency | 1 | 2026 | 50 | 0.060 |
Why?
|
| Publications | 1 | 2005 | 36 | 0.060 |
Why?
|
| Tissue Donors | 1 | 2009 | 506 | 0.060 |
Why?
|
| Biotechnology | 1 | 2005 | 59 | 0.060 |
Why?
|
| Contract Services | 1 | 2005 | 3 | 0.060 |
Why?
|
| Lawyers | 1 | 2005 | 5 | 0.060 |
Why?
|
| Ethics, Institutional | 1 | 2005 | 14 | 0.050 |
Why?
|
| Perception | 1 | 2026 | 231 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 2602 | 0.050 |
Why?
|
| DNA | 1 | 2010 | 1399 | 0.050 |
Why?
|
| Cell Line | 1 | 2009 | 2552 | 0.050 |
Why?
|
| Cryopreservation | 1 | 2005 | 79 | 0.050 |
Why?
|
| Interprofessional Relations | 1 | 2005 | 149 | 0.050 |
Why?
|
| Infant | 2 | 2016 | 13352 | 0.050 |
Why?
|
| Prejudice | 1 | 2004 | 39 | 0.050 |
Why?
|
| Self-Management | 1 | 2025 | 120 | 0.050 |
Why?
|
| Atrophy | 1 | 2024 | 247 | 0.050 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2004 | 129 | 0.050 |
Why?
|
| Transition to Adult Care | 1 | 2025 | 131 | 0.050 |
Why?
|
| Research | 1 | 2005 | 264 | 0.050 |
Why?
|
| Risk Factors | 1 | 2017 | 11074 | 0.050 |
Why?
|
| Texas | 2 | 2024 | 3686 | 0.050 |
Why?
|
| Patient Satisfaction | 1 | 2026 | 464 | 0.050 |
Why?
|
| Research Personnel | 1 | 2024 | 139 | 0.050 |
Why?
|
| Middle Aged | 5 | 2026 | 28601 | 0.050 |
Why?
|
| Exploratory Behavior | 1 | 2022 | 52 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2004 | 555 | 0.040 |
Why?
|
| Child | 4 | 2024 | 26341 | 0.040 |
Why?
|
| Family | 1 | 2024 | 589 | 0.040 |
Why?
|
| Intellectual Property | 1 | 2019 | 9 | 0.040 |
Why?
|
| Caregivers | 1 | 2025 | 598 | 0.040 |
Why?
|
| North Carolina | 1 | 2019 | 48 | 0.040 |
Why?
|
| Pregnancy | 1 | 2012 | 7512 | 0.040 |
Why?
|
| California | 1 | 2019 | 127 | 0.040 |
Why?
|
| Attitude | 1 | 2019 | 111 | 0.030 |
Why?
|
| Pedigree | 1 | 2022 | 1677 | 0.030 |
Why?
|
| Trust | 1 | 2019 | 91 | 0.030 |
Why?
|
| Professional-Family Relations | 1 | 2018 | 99 | 0.030 |
Why?
|
| Information Services | 1 | 2017 | 23 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2013 | 12936 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2026 | 5196 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2018 | 245 | 0.030 |
Why?
|
| Consent Forms | 1 | 2016 | 22 | 0.030 |
Why?
|
| Death | 1 | 2016 | 78 | 0.030 |
Why?
|
| Health Status | 1 | 2017 | 378 | 0.030 |
Why?
|
| Social Media | 1 | 2017 | 120 | 0.030 |
Why?
|
| Health Facility Merger | 1 | 2015 | 8 | 0.030 |
Why?
|
| Organizational Culture | 1 | 2016 | 95 | 0.030 |
Why?
|
| Models, Organizational | 1 | 2015 | 43 | 0.030 |
Why?
|
| North America | 1 | 2014 | 255 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2013 | 89 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2014 | 3711 | 0.010 |
Why?
|
| Consultants | 1 | 2005 | 13 | 0.010 |
Why?
|
| Hospital Administration | 1 | 2005 | 24 | 0.010 |
Why?
|
| Conflict of Interest | 1 | 2005 | 66 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2016 | 8635 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2016 | 15110 | 0.010 |
Why?
|
| Aged | 1 | 2017 | 21025 | 0.010 |
Why?
|